Histamine-4 Receptor: Emerging Target for the Treatment of Neurological Diseases

Overview

Journal Curr Top Behav Neurosci

Publisher Springer

Specialty Psychology

Date 2021 Aug 25

PMID 34432256

Citations 2

Authors

Ling Shan

Gerard J M Martens

Dick F Swaab

Affiliations

Soon will be listed here.

Abstract

A major challenge in the field of the biogenic amine histamine is the search for new-generation histamine receptor specific drugs. Daniel Bovet and Sir James Black received their Nobel Prizes for Medicine for their work on histamine-1 receptor (HR) and HR antagonists to treat allergies and gastrointestinal disorders. The first HR-targeting drug to reach the market was approved for the treatment of the neurological disorder narcolepsy in 2018. The antagonists for the most recently identified histamine receptor, HR, are currently under clinical evaluation for their potential therapeutic effects on inflammatory diseases such as atopic dermatitis and pruritus. In this chapter, we propose that HR antagonists are endowed with prominent anti-inflammatory and immune effects, including in the brain. To substantiate this proposition, we combine data from transcriptional analyses of postmortem human neurodegenerative disease brain samples, human genome-wide association studies (GWAS), and translational animal model studies. The results prompt us to suggest the potential involvement of the HR in various neurodegenerative diseases and how manipulating the HR may create new therapeutic opportunities in central nervous system diseases.

Citing Articles

Histamine H Receptor Isoforms: Insights from Alternative Splicing to Functional Complexity.

Gao M, Ooms J, Leurs R, Vischer H Biomolecules. 2024; 14(7).

PMID: 39062475 PMC: 11274711. DOI: 10.3390/biom14070761.

Synthesis and Pharmacological Characterization of New Photocaged Agonists for Histamine H and H Receptors.

Zheng Y, Gao M, Wijtmans M, Vischer H, Leurs R Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675496 PMC: 11053687. DOI: 10.3390/ph17040536.

References

Anaclet C, Parmentier R, Ouk K, Guidon G, Buda C, Sastre J . Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci. 2009; 29(46):14423-38. PMC: 2802289. DOI: 10.1523/JNEUROSCI.2604-09.2009. View

Apolloni S, Fabbrizio P, Amadio S, Napoli G, Verdile V, Morello G . Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis. Front Immunol. 2017; 8:1689. PMC: 5714870. DOI: 10.3389/fimmu.2017.01689. View

Apolloni S, Amadio S, Fabbrizio P, Morello G, Spampinato A, Latagliata E . Histaminergic transmission slows progression of amyotrophic lateral sclerosis. J Cachexia Sarcopenia Muscle. 2019; 10(4):872-893. PMC: 6711424. DOI: 10.1002/jcsm.12422. View

Aronica E, Baas F, Iyer A, Ten Asbroek A, Morello G, Cavallaro S . Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol Dis. 2014; 74:359-76. DOI: 10.1016/j.nbd.2014.12.002. View

Arrang J, Garbarg M, Schwartz J . Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience. 1985; 15(2):553-62. DOI: 10.1016/0306-4522(85)90233-7. View

Arrang J, Schwartz J, Schunack W . Stereoselectivity of the histamine H3-presynaptic autoreceptor. Eur J Pharmacol. 1985; 117(1):109-14. DOI: 10.1016/0014-2999(85)90478-9. View

Arrang J, Devaux B, Chodkiewicz J, Schwartz J . H3-receptors control histamine release in human brain. J Neurochem. 1988; 51(1):105-8. DOI: 10.1111/j.1471-4159.1988.tb04841.x. View

Arrang J, Defontaine N, Schwartz J . Phencyclidine blocks histamine H3-receptors in rat brain. Eur J Pharmacol. 1988; 157(1):31-5. DOI: 10.1016/0014-2999(88)90467-0. View

Athauda D, Maclagan K, Skene S, Bajwa-Joseph M, Letchford D, Chowdhury K . Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390(10103):1664-1675. PMC: 5831666. DOI: 10.1016/S0140-6736(17)31585-4. View

10.

Beermann S, Seifert R, Neumann D . Commercially available antibodies against human and murine histamine H₄-receptor lack specificity. Naunyn Schmiedebergs Arch Pharmacol. 2011; 385(2):125-35. DOI: 10.1007/s00210-011-0700-4. View

11.

Betarbet R, Sherer T, MacKenzie G, Panov A, Greenamyre J . Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000; 3(12):1301-6. DOI: 10.1038/81834. View

12.

Bian Z, Gong Y, Huang T, Lee C, Bian L, Bai Z . Deciphering human macrophage development at single-cell resolution. Nature. 2020; 582(7813):571-576. DOI: 10.1038/s41586-020-2316-7. View

13.

Boillee S, Yamanaka K, Lobsiger C, Copeland N, Jenkins N, Kassiotis G . Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006; 312(5778):1389-92. DOI: 10.1126/science.1123511. View

14.

Brabant C, Charlier Y, Serrano Navacerrada M, Alleva L, Tirelli E . Action of Pitolisant on the stimulant and rewarding effects of cocaine in mice. Eur J Pharmacol. 2016; 791:552-559. DOI: 10.1016/j.ejphar.2016.08.027. View

15.

Chiot A, Zaidi S, Iltis C, Ribon M, Berriat F, Schiaffino L . Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat Neurosci. 2020; 23(11):1339-1351. DOI: 10.1038/s41593-020-00718-z. View

16.

Cicchetti F, Drouin-Ouellet J, Gross R . Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol Sci. 2009; 30(9):475-83. DOI: 10.1016/j.tips.2009.06.005. View

17.

DALE H, Laidlaw P . The physiological action of beta-iminazolylethylamine. J Physiol. 1910; 41(5):318-44. PMC: 1512903. DOI: 10.1113/jphysiol.1910.sp001406. View

18.

Dauvilliers Y, Bassetti C, Lammers G, Arnulf I, Mayer G, Rodenbeck A . Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013; 12(11):1068-75. DOI: 10.1016/S1474-4422(13)70225-4. View

19.

Desmadryl G, Gaboyard-Niay S, Brugeaud A, Travo C, Broussy A, Saleur A . Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. Br J Pharmacol. 2012; 167(4):905-16. PMC: 3575788. DOI: 10.1111/j.1476-5381.2012.02049.x. View

20.

Dong H, Zhang W, Zeng X, Hu G, Zhang H, He S . Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia. Mol Neurobiol. 2014; 49(3):1487-500. DOI: 10.1007/s12035-014-8697-6. View